Finn Skou Pedersen

iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark.

EnFutech ApS is a holding company that develops technologies for prevention, treatment, and eradication of Human Immunodeficiency Virus (HIV). Its platforms include both a new type of inhibitor that can be used as a prophylactic agent as well as a traditional drug for treatment of infection and a gene therapeutical approach to rendering the T-cells immune to HIV infection. The firm aims to combat infection, by developing effective anti-HIV treatments that can remove the virus both before and after it infects human cells. Its treatment is based on its novel technologies of blocking the HIV co-receptors using retargeted envelope proteins and receptor interference. The company was founded by Finn Skou Pedersen and Martin Tolstrup on August 23, 2007 and is headquartered in Aarhus, Denmark.